Silence Therapeutics CFO steps down

The AIM-listed drug discovery and development outfit has tapped Dr Rob Quinn, its head of financial planning and analysis, to take over as interim chief financial officer until such a time as a permanent CFO is found.

Chief executive Dr David Horn Solomon, who took over the role just six months ago, said: "On behalf of the board I would like to thank David for his contribution to Silence.

"He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space."

Back in September, Silence Therapeutics reported a first half loss after tax of £8.7m, up 57%, due to costs associated with bringing its two lead programmes towards the clinic.

As of 1040 GMT, Silence shares had picked up 1.88% to 54.20p.